 RespireRx Pharmaceuticals OTCQB:RSPI said it has signed a letter of intent with a bespoke clinical research organization in Australia that focuses on cannabinoid and psychedelic clinical research. Upon reaching a definitive contract, RespireRx said it will make a US50,000 deposit to be applied to the final studies budget and credited against the first invoice. 